Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (Stribild) for the treatment of HIV in teenagers


The fixed-dose combination of the four drugs elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (trade name: Stribild) has been approved in Germany since October 2017 for the treatment of HIV type 1 in teenagers over the age of 12. The fixed-dose combination is an option if medication without the drug tenofovir disoproxil can't be used due to side effects.

The human immunodeficiency (HIV) multiplies in cells of the and destroys them. Without proper treatment, the immune system of most HIV patients is weakened so much that they become seriously ill. This stage is referred to as AIDS (acquired immune deficiency syndrome).

Although the currently available medications can't cure HIV, they can prevent immunodeficiency for many years. But the medication can become ineffective over time, allowing the viruses to multiply more again.


The fixed-dose combination including elvitegravir is taken in the form of a tablet, once a day with a meal. One tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil.

Other treatments

Teenagers with HIV are generally given individually tailored treatment for HIV. This type of treatment takes into consideration factors like which treatments were tried before and why they were stopped. For instance, the previous treatment may not have worked or may have caused side effects.


In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to find out whether the fixed-dose combination of elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil has any advantages or disadvantages compared with standard treatments for HIV type 1 in teenagers.

But the manufacturer didn't provide any data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of this review and the hearings received, the G-BA passed a resolution on the added benefit of elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (Stribild).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V. Dossier assessment; Commission A17-59. February 07, 2018. (IQWiG reports; Volume 596).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on February 15, 2018
Next planned update: 2021


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.